Eli Lilly Agrees to Acquire ICOS for $2.1 Billion
Indianapolis, IN (Oct. 17)-Eli Lilly and Company agreed to acquire ICOS Corporation (Bothell, WA) for $2.1 billion.
Indianapolis, IN (Oct. 17)-Eli Lilly and Company (www.lilly.com) agreed to acquire ICOS Corporation (Bothell, WA, www.icos.com) for $2.1 billion.
The companies have partnered since 1998 in Lilly ICOS LLC, a joint venture that manufactures, markets and sells “Cialis” (tadalafil), an oral PDE-5 inhibitor. Cialis had global sales of $465 million in the first half of 2006.
The deal is expected to close in late 2006 or early 2007.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
